Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy
Melanie A. Krook(The Ohio State University), Sameek Roychowdhury(The Ohio State University Wexner Medical Center), Julie W. Reeser(The Ohio State University), Jharna Miya(The Ohio State University), Dorrelyn M. Martin(The Ohio State University), Cynthia Timmers(Cancer Genetics (United States)), Lianbo Yu(The Ohio State University), Aharon G. Freud(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Russell Bonneville(The Ohio State University), Kaitlin R. Baker(The Ohio State University), Kristin Dittmar(The Ohio State University), Anoosha Paruchuri(The Ohio State University), Amy Smith(The Ohio State University), Patricia Allenby(The Ohio State University), Thuy Dao(The Ohio State University), Eric Samorodnitsky(The Ohio State University), Hui‐Zi Chen(Medical College of Wisconsin), Michele R. Wing(The Ohio State University)
Cited by 88
Related Papers
Landscape of Microsatellite Instability Across 39 Cancer Types
|JCO Precision Oncology|2017|1.5k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
|Nature Genetics|2013|818
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
|Cancer Discovery|2013|737